|
1
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T,
Sohara Y, Sugiyama Y and Mano H: Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature.
448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dearden S, Stevens J, Wu YL and Blowers D:
Mutation incidence and coincidence in non small-cell lung cancer:
meta-analyses by ethnicity and histology (mutMap). Ann Oncol.
24:2371–2376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer Society. Cancer Facts and
Figures 2013. American Cancer Society; Atlanta, GA: 2013
|
|
4
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB,
Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman
JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve
SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K,
Salgia R, Shapiro GI, Clark JW and Iafrate AJ: Anaplastic lymphoma
kinase inhibition in non-small-cell lung cancer. N Engl J Med.
363:1693–1703. 2010.Erratum appeared in 364: 588, 2011.
|
|
6
|
Kim DW, Ahn MJ, Shi Y, De Pas TM, Yang PC,
Riely GJ, Crinò L, Evans TL, Liu X, Han JY, Salgia R, Moro-Sibilot
D, Ou SHI, Gettinger SN, Wu YL, Lanzalone S, Polli A, Iyer S and
Shaw AT: Results of a global phase II study with crizotinib in
advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin
Oncol. 30:2012.(Suppl; abst 7533).
|
|
7
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL,
Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V,
Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD and Jänne PA:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaw AT, Solomon B and Kenudson MM:
Crizotinib and testing for ALK. J Natl Compr Cancer Netw.
9:1335–1341. 2011.PubMed/NCBI
|
|
9
|
Thunnissen E, Bubendorf L, Dietel M,
Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P,
Penault-Llorca F and Rossi G: EML4-ALK testing in non-small cell
carcinomas of the lung: a review with recommendations. Virchows
Arch. 461:245–257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wynes MW, Dietel M, Schuuring E, Sholl LM,
Tsao M, Yatabe Y, Tubbs RR and Hirsch F: An international
standardization study using the ALK IHC antibody D5F3 and a
sensitive detection kit demonstrates high concordance between ALK
IHC and ALK FISH and between evaluators. J Thorac Oncol. 8(Suppl
2)2013.(abst O04.06).
|
|
11
|
Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu
X and Lu N: Diagnostic value of a novel fully automated
immunochemistry assay for detection of ALK rearrangement in primary
lung adenocarcinoma. Ann Oncol. 24:2589–2593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Camidge DR, Skokan M, Kiatsimkul P,
Helfrich B, Lu X, Barón AE, Schulte N, Maxson D, Aisner DL,
Franklin WA, Doebele RC and Varella-Garcia M: Native and rearranged
ALK copy number and rearranged cell count in non-small cell lung
cancer: Implications for ALK inhibitor therapy. Cancer.
119:3968–3975. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peled N, Palmer G, Hirsch FR, Wynes MW,
Ilouze M, Varella-Garcia M, Soussan-Gutman L, Otto GA, Stephens PJ,
Ross JS, Cronin MT, Lipson D and Miller VA: Next-generation
sequencing identifies and immunohistochemistry confirms a novel
crizotinib-sensitive ALK rearrangement in a patient with metastatic
non-small-cell lung cancer. J Thorac Oncol. 7:e14–e16. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren S, Hirsch FR, Varella-Garcia M, Aisner
DL, Boyle T, Zhou C and Camidge DR: Atypical negative ALK
break-apart FISH harboring a crizotinib-responsive ALK
rearrangement in non-small-cell lung cancer. J Thorac Oncol.
9:e21–e23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hotta K, Suzuki E, Di Maio M, Chiodini P,
Fujiwara Y, Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L,
Hisamoto-Sato A, Tabata M, Tanimoto M, Shepherd FA and Kiura K:
Progression-free survival and overall survival in phase III trials
of molecular-targeted agents in advanced non-small-cell lung
cancer. Lung Cancer. 79:20–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gridelli C, de Marinis F, Cappuzzo F, Di
Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC
and Ciardiello F: Treatment of advanced non-small-cell lung cancer
with epidermal growth factor receptor (EGFR) mutation or ALK gene
rearrangement: results of an International Expert Panel Meeting of
the Italian Association of Thoracic Oncology. Clin Lung Cancer.
15:173–181. 2014. View Article : Google Scholar
|
|
17
|
Shaw AT, Yeap BY, Solomon BJ, Riely GJ,
Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M,
Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K,
Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ and
Camidge DR: Effect of crizotinib on overall survival in patients
with advanced non-small-cell lung cancer harbouring ALK gene
rearrangement: a retrospective analysis. Lancet Oncol.
12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Doebele RC, Pilling AB, Aisner DL,
Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ,
Heasley LE, Franklin WA, Varella-Garcia M and Camidge DR:
Mechanisms of resistance to crizotinib in patients with ALK gene
rearranged non-small cell lung cancer. Clin Cancer Res.
18:1472–1482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim S, Kim TM, Kim DW, Go H, Keam B, Lee
SH, Ku JL, Chung DH and Heo DS: Heterogeneity of genetic changes
associated with acquired crizotinib resistance in ALK-rearranged
lung cancer. J Thorac Oncol. 8:415–422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peters S, Taron M, Bubendorf L, Blackhall
F and Stahel R: Treatment and detection of ALK-rearranged NSCLC.
Lung Cancer. 81:145–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E,
Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ,
Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY,
Goldwasser M, Boral AL and Engelman JA: Ceritinib in ALK-rearranged
non-small-cell lung cancer. N Engl J Med. 370:1189–1197. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gainor JF, Ou SH, Logan J, Borges LF and
Shaw AT: The central nervous system as a sanctuary site in
ALK-positive non-small-cell lung cancer. J Thorac Oncol.
8:1570–1573. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Camidge DR, Kono SA, Lu X, Okuyama S,
Barón AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W and
Doebele RC: Anaplastic lymphoma kinase gene rearrangements in
non-small cell lung cancer are associated with prolonged
progression-free survival on pemetrexed. J Thorac Oncol. 6:774–780.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JO, Kim TM, Lee SH, Kim DW, Kim S,
Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS and Bang
YJ: Anaplastic lymphoma kinase translocation: a predictive
biomarker of pemetrexed in patients with non-small cell lung
cancer. J Thorac Oncol. 6:1474–1480. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gan GN, Weickhardt AJ, Scheier B, Doebele
RC, Gaspar LE, Kavanagh BD and Camidge DR: Stereotactic radiation
therapy can safely and durably control sites of extra-central
nervous system oligoprogressive disease in anaplastic lymphoma
kinase-positive lung cancer patients receiving crizotinib. Int J
Radiat Oncol Biol Phys. 88:892–898. 2014. View Article : Google Scholar
|
|
26
|
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ,
Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW,
Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB,
Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K,
Clark JW and Shaw AT: Activity and safety of crizotinib in patients
with ALK-positive non-small-cell lung cancer: updated results from
a phase 1 study. Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim
DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW and Riely
GJ: Clinical benefit of continuing ALK inhibition with crizotinib
beyond initial disease progression in patients with advanced
ALK-positive NSCLC. Ann Oncol. 25:415–422. 2014. View Article : Google Scholar
|
|
28
|
Chen Z, Akbay EA, Mikse OR, Tupper T,
Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel J, Janne
PA, Engelman JA, Sharpless NE, Kung AL, Shapiro GI and Wong KK:
Co-clinical trials demonstrate superiority of crizotinib to
chemotherapy in ALK-rearranged non-small cell lung cancer and
predict strategies to overcome resistance. Clin Cancer Res.
20:1204–1211. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li T, Maus MK, Desai SJ, Beckett LA,
Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH and
Gandara DR: Large-scale screening and molecular characterization of
EML4-ALK fusion variants in archival non-small-cell lung cancer
tumor specimens using quantitative reverse transcription polymerase
chain reaction assays. J Thorac Oncol. 9:18–25. 2014. View Article : Google Scholar
|
|
30
|
Berge EM, Lu X, Maxson D, Barón AE,
Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M and Camidge
DR: Clinical benefit from pemetrexed before and after crizotinib
exposure and from crizotinib before and after pemetrexed exposure
in patients with anaplastic lymphoma kinase-positive non-small-cell
lung cancer. Clin Lung Cancer. 14:636–643. 2013. View Article : Google Scholar
|
|
31
|
Shaw AT, Varghese AM, Solomon BJ, Costa
DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ,
Monica V, Yeap BY and Scagliotti GV: Pemetrexed-based chemotherapy
in patients with advanced, ALK-positive non-small cell lung cancer.
Ann Oncol. 24:59–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim MH, Shim HS, Kang DR, Jung JY, Lee CY,
Kim DJ, Lee JG, Bae MK, Kim HR, Lim SM, Kim EY, Park JS, Chung KY,
Kim HJ, Kim JH and Cho BC: Clinical and prognostic implications of
ALK and ROS1 rearrangements in never-smokers with surgically
resected lung adenocarcinoma. Lung Cancer. 83:389–395. 2014.
View Article : Google Scholar : PubMed/NCBI
|
